Key facts
- GelMEDIX’s last known valuation is $21.0M (Feb 2026).
- It has raised $30.7M across 4 recorded rounds; the latest was Seed Round ($747K) in Oct 2025.
- Notable investors include Safar Partners, Beacon Angels, TiE Angels Boston, Boston Harbor Angels, EQx Fund — 6 tracked in total.
- GelMEDIX has filed 6 Form Ds with the SEC since 2020, most recently Apr 2026 ($747K sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for GelMEDIX
Funding rounds
4 roundsAbout GelMEDIX
Developer of a light-activated biomaterial platform designed to bring innovation in ocular and regenerative therapies. The company's platform focuses on bio-adhesion, tissue regeneration, tunable mechanics and therapeutic loading across modalities from small molecules to cell and gene therapies through its photo-crosslinked hydrogels, enabling medical professionals to perform cell-based therapies for vision restoration, intraocular sustained release of small molecules and peptides and in situ forming bioadhesives.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 5
- Website
- gelmedix.com/
- Ownership
- Privately Held (backing)
GelMEDIX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GelMEDIX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GelMEDIX in its N-PORT filings yet. We sweep new filings monthly.